Basic Information
RNALocate ID: | RLID-D:11000396 |
RNA Symbol: | hsa-miR-200a-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-200a-3p |
RNA ID: | miRBase:MIMAT0000682 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
Tissue/Cell Line: | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
Database: | EVmiRNA |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001986 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11002343 | Exosome | Human milk | 28688106 |
RLID:11002344 | Exosome | Pulmonary epithelial cell line (BEAS-2B) | 31520698 |
RLID:11002345 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11002346 | Exosome | Ascites fluid|Pleural effusion | 21601258 |
RLID:11002347 | Exosome | Breast milk | 22211110 |
RLID:11002348 | Exosome | Brain tissue | 23382797 |
RLID:11002349 | Exosome | Plasma | 23663360 |
RLID:11002350 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000109 | Exosome | Breast milk|Colon tissue|Seminal fluid|Tongue tissue |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-200a-3p | Splenic marginal zone lymphoma | MNDR-E-MI-25845 |
MNDR | hsa-miR-200a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-25846 |
MNDR | hsa-miR-200a-3p | Oral squamous cell carcinoma | MNDR-E-MI-25847 |
MNDR | hsa-miR-200a-3p | Large cell neuroendocrine cancer | MNDR-E-MI-25848 |
MNDR | hsa-miR-200a-3p | Mucosa-associated lymphoid tissue lymphoma | MNDR-E-MI-25849 |
MNDR | hsa-miR-200a-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-25850 |
MNDR | hsa-miR-200a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-25851 |
MNDR | hsa-miR-200a-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-25852 |
MNDR | hsa-miR-200a-3p | Lymphoma non-hodgkin | MNDR-E-MI-25853 |
MNDR | hsa-miR-200a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-25854 |
MNDR | hsa-miR-200a-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-25855 |
MNDR | hsa-miR-200a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-25856 |
MNDR | hsa-miR-200a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-25857 |
MNDR | hsa-miR-200a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-25858 |
MNDR | hsa-miR-200a-3p | Triple negative breast cancer | MNDR-E-MI-25859 |
MNDR | hsa-miR-200a-3p | Breast cancer luminal | MNDR-E-MI-25860 |
MNDR | hsa-miR-200a-3p | Small intestine cancer | MNDR-E-MI-25861 |
MNDR | hsa-miR-200a-3p | Prostate cancer | MNDR-E-MI-25862 |
MNDR | hsa-miR-200a-3p | Gastric cancer | MNDR-E-MI-25863 |
MNDR | hsa-miR-200a-3p | Gastric lymphoma | MNDR-E-MI-25864 |
MNDR | hsa-miR-200a-3p | Alzheimer disease | MNDR-E-MI-25865 |
MNDR | hsa-miR-200a-3p | Bladder cancer | MNDR-E-MI-25866 |
MNDR | hsa-miR-200a-3p | Polycystic ovary syndrome | MNDR-E-MI-25867 |
MNDR | hsa-miR-200a-3p | Head and neck cancer | MNDR-E-MI-25868 |
MNDR | hsa-miR-200a-3p | Leukemia | MNDR-E-MI-25869 |
MNDR | hsa-miR-200a-3p | Huntington disease | MNDR-E-MI-25870 |
MNDR | hsa-miR-200a-3p | Cardiovascular disease | MNDR-E-MI-25871 |
MNDR | hsa-miR-200a-3p | Brain cancer | MNDR-E-MI-25872 |
MNDR | hsa-miR-200a-3p | Lung cancer | MNDR-E-MI-25873 |
MNDR | hsa-miR-200a-3p | Endometrial cancer | MNDR-E-MI-25874 |
MNDR | hsa-miR-200a-3p | Parkinson disease | MNDR-E-MI-25875 |
MNDR | hsa-miR-200a-3p | Machado-joseph disease | MNDR-E-MI-25876 |
MNDR | hsa-miR-200a-3p | Breast cancer | MNDR-E-MI-25877 |
MNDR | hsa-miR-200a-3p | Cancer | MNDR-E-MI-25878 |
MNDR | hsa-miR-200a-3p | Thyroid cancer | MNDR-E-MI-25879 |
MNDR | hsa-miR-200a-3p | Pituitary neoplasms | MNDR-E-MI-25880 |
MNDR | hsa-miR-200a-3p | Pancreatic cancer | MNDR-E-MI-25881 |
MNDR | hsa-miR-200a-3p | Melanoma | MNDR-E-MI-25882 |
MNDR | hsa-miR-200a-3p | Rectum adenocarcinoma | MNDR-E-MI-25883 |
MNDR | hsa-miR-200a-3p | Nephroblastoma | MNDR-E-MI-25884 |
MNDR | hsa-miR-200a-3p | Colon cancer | MNDR-E-MI-25885 |
MNDR | hsa-miR-200a-3p | Ischemic attack transient | MNDR-E-MI-25886 |
MNDR | hsa-miR-200a-3p | Colon adenocarcinoma | MNDR-E-MI-25887 |
MNDR | hsa-miR-200a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-25888 |
MNDR | hsa-miR-200a-3p | Ovarian cancer | MNDR-E-MI-25889 |
MNDR | hsa-miR-200a-3p | Endometrial endometrioid carcinoma | MNDR-E-MI-25890 |
MNDR | hsa-miR-200a-3p | Carcinoma ductal breast | MNDR-E-MI-25891 |
MNDR | hsa-miR-200a-3p | Glioblastoma | MNDR-E-MI-25892 |
MNDR | hsa-miR-200a-3p | Glioma | MNDR-E-MI-25893 |
MNDR | hsa-miR-200a-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-25894 |
MNDR | hsa-miR-200a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-25895 |
MNDR | hsa-miR-200a-3p | Epilepsy temporal lobe | MNDR-E-MI-25896 |
MNDR | hsa-miR-200a-3p | Osteosarcoma | MNDR-E-MI-25897 |
MNDR | hsa-miR-200a-3p | Breast carcinoma | MNDR-E-MI-25898 |
MNDR | hsa-miR-200a-3p | Meningioma | MNDR-E-MI-25899 |
MNDR | hsa-miR-200a-3p | Uterine cancer | MNDR-E-MI-25900 |
MNDR | hsa-miR-200a-3p | Cervical adenocarcinoma | MNDR-E-MI-25901 |
MNDR | hsa-miR-200a-3p | Gastric adenocarcinoma | MNDR-E-MI-25902 |
MNDR | hsa-miR-200a-3p | Cervical squamous cell carcinoma | MNDR-E-MI-25903 |
MNDR | hsa-miR-200a-3p | Pituitary adenoma | MNDR-E-MI-25904 |
MNDR | hsa-miR-200a-3p | Lung squamous cell carcinoma | MNDR-E-MI-25905 |
MNDR | hsa-miR-200a-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-25906 |
MNDR | hsa-miR-200a-3p | Lung adenocarcinoma | MNDR-E-MI-25907 |
MNDR | hsa-miR-200a-3p | Papillary thyroid carcinoma | MNDR-E-MI-25908 |
MNDR | hsa-miR-200a-3p | Ovarian carcinoma | MNDR-E-MI-25909 |
MNDR | hsa-miR-200a-3p | Bladder urothelial carcinoma | MNDR-E-MI-25910 |
MNDR | hsa-miR-200a-3p | Carcinoma renal cell | MNDR-E-MI-25911 |
MNDR | hsa-miR-200a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-25912 |
MNDR | hsa-miR-200a-3p | Clear cell renal cell carcinoma | MNDR-E-MI-25913 |
MNDR | hsa-miR-200a-3p | Biliary tract cancer | MNDR-E-MI-25914 |
MNDR | hsa-miR-200a-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-25915 |
MNDR | hsa-miR-200a-3p | Cholangiocarcinoma | MNDR-E-MI-25916 |
MNDR | hsa-miR-200a-3p | Liver cirrhosis | MNDR-E-MI-25917 |
MNDR | hsa-miR-200a-3p | Lung small cell carcinoma | MNDR-E-MI-25918 |
MNDR | hsa-miR-200a-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-25919 |
MNDR | hsa-miR-200a-3p | Testicular germ cell cancer | MNDR-E-MI-25920 |
MNDR | hsa-miR-200a-3p | Breast invasive carcinoma | MNDR-E-MI-25921 |
MNDR | hsa-miR-200a-3p | Early hepatocellular carcinoma | MNDR-E-MI-25922 |
MNDR | hsa-miR-200a-3p | B-cell lymphoma | MNDR-E-MI-25923 |
MNDR | hsa-miR-200a-3p | T-cell leukemia | MNDR-E-MI-25924 |
MNDR | hsa-miR-200a-3p | Malignant pleural mesothelioma | MNDR-E-MI-25925 |
MNDR | hsa-miR-200a-3p | Retinoblastoma | MNDR-E-MI-25926 |
MNDR | hsa-miR-200a-3p | Barrett's adenocarcinoma | MNDR-E-MI-25927 |
MNDR | hsa-miR-200a-3p | Hodgkin lymphoma | MNDR-E-MI-25928 |
MNDR | hsa-miR-200a-3p | Burkitt lymphoma | MNDR-E-MI-25929 |
MNDR | hsa-miR-200a-3p | Psoriasis | MNDR-E-MI-25930 |
MNDR | hsa-miR-200a-3p | Skin cutaneous melanoma | MNDR-E-MI-25931 |
MNDR | hsa-miR-200a-3p | Skin melanoma | MNDR-E-MI-25932 |
MNDR | hsa-miR-200a-3p | Colorectal cancer | MNDR-E-MI-25933 |
MNDR | hsa-miR-200a-3p | Nasopharyngeal carcinoma | MNDR-E-MI-25934 |
MNDR | hsa-miR-200a-3p | Multiple myeloma | MNDR-E-MI-25935 |
MNDR | hsa-miR-200a-3p | Ovarian epithelial cancer | MNDR-E-MI-25936 |
MNDR | hsa-miR-200a-3p | Uterine cervical neoplasms | MNDR-E-MI-25937 |
MNDR | hsa-miR-200a-3p | Ependymoma | MNDR-E-MI-25938 |
MNDR | hsa-miR-200a-3p | Nasopharyngeal cancer | MNDR-E-MI-25939 |
MNDR | hsa-miR-200a-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-25940 |
MNDR | hsa-miR-200a-3p | Barrett's carcinogenesis | MNDR-E-MI-25941 |
MNDR | hsa-miR-200a-3p | Breast cancer her3+ negative | MNDR-E-MI-25942 |
MNDR | hsa-miR-200a-3p | High grade dysplastic nodule | MNDR-E-MI-25943 |
MNDR | hsa-miR-200a-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-25944 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | AGER | Homo sapiens | RR00054548 |
TOP